BLOG

HPV-Cancer Targeting Immunotherapy Enters Phase 1 Clinical Trial After Showing Success In Animals

This week the publishing of data on Cue Biopharma’s star immunotherapy molecule, Cue 101, revealed just how much reality there is to concept. A paper published in Clinical Cancer Research on Tuesday showed research demonstrating the ability of a biologic immunotherapy drug candidate named CUE-101 to activate tumor antigen-specific antitumor immunity.